Get your extra portion of EIT Health Germany news...
EIT Health Germany Newsletter
Dear EIT Health Partners and Friends,
The first weeks of 2021 have already passed and I hope you all got off to a safe and successful start to the new year. This month's newsletter has a lot of exciting opportunities in store for you, so please do read on!
I am particularly happy to announce that the EIT Health Germany flagship programme Start-Ups Meet Pharma 2021 is officially open for applications. In 2021, five pharma companies: Takeda, Abbot, Merck, Amgen and AstraZeneca will open their innovation departments and explore collaborations with start-ups through the SMP2021 programme. Past editions of the programme have proven to be very beneficial to former participants with many NDAs signed, clinical trials kicked-off and collaborative projects in the works. Read on further below to find out more about just how successful the programme was and how to become involved.
Enjoy the read!
Dr. Katharina Ladewig
Managing Director EIT Health Germany
Monthly Focus - Applications now open for Start-Ups Meet Pharma 2021
Hey healthcare innovators, are you ready for a challenge? Are you working in the field of Chronic Kidney Disease? Or maybe Multiple Sclerosis? Or maybe your solution helps with the diagnosis of Adult ADHD? If you answered with 'yes' on any or all these questions, then we have a great opportunity for you.
We are delighted to announce the opening of the call for applications for Start-ups Meet Pharma 2021. This challenge-based acceleration programme connects key pharma partners in Europe with startups at the forefront of technological innovation. In 2021, we have partnered with five Pharma companies, Takeda, Abbot, Merck, Amgen and AstraZeneca as our challenge-providers, and we now invite start-ups to address the set challenges with their products and services. Deadline: 16 March 2021.
Further information about the programme and the 2021 challenges can be found here.
What's coming up?
The EIT Health Accelerator Catalogue 2021 is out!
We invite entrepreneurs, start-ups and SMEs to submit applications to our programmes and accelerate their growth. Whether you need access to knowledge, new markets, key stakeholders, or investors and funding – EIT Health can help.
EIT Health has partnered with Dealroom to create a dedicated EIT Health Start-up platform, enabling users to track the latest developments of our start-ups within the ecosystem and making the EIT Health pipeline transparent and visible.
Venture capital funds interested in healthcare innovations can now apply to cooperate with the Venture Centre of Excellence (VCoE) through the Call for Expressions of Interest published by the European Investment Fund (EIF).
Big success for 24-hour care: DIN Standard for exemplary home care published
Congratulations to Mecasa, our 2019 Headstart Programme finalist, for successfully initiating the first DIN Standard for qualitative 24h care. DIN SPEC 33454 sets an important impulse for legal and social balance and is intended to provide standardised protection for customers and caregivers alike. For the first time, the strict requirements of the new quality standard differentiate between nurse-provided care and unqualified personnel placement. The new quality standard is not Mecasa’s only project in exemplary home care. Their digital placement platform with a psychological matching model has reduced the dropout rate of caregiver relationships from 31 to 12 percent.
RWTH Aachen University's spin-off and EIT Health Catapult finalist Medical Magnesium is ready for EU market entry thanks to their recent achievement of the CE Mark being granted to their resorbable implant systems based on mm.X technology. Medical magnesium's metallic bioabsorbable implants for orthopedic and trauma surgery are made of magnesium. The implants are mechanically stable and physiologically degradable after fracture healing, leading to a minimal amount of intervention and effective innovative patient care. “Our vision is to enable surgeons to improve patient care through our highly functional resorbable mm.X implants. Our first market approvals now open up exactly this path and more implants […] are already in development,” states Kilian Reuß, CEO and Co-founder.
Manfred Heinzer joins EIT Health Germany Supervisory Board
A warm welcome to Manfred Heinzer, Vice President and General Manager of Amgen Germany, as a new member of the EIT Health Germany Supervisory Board, representing the DACH region within EIT Health's 150+ member strong, pan-European network.
Curious to see the faces behind EIT Health Germany? Click here for more information on our Supervisory Board members (German only).
We look forward to our continued work together in 2021!
Making cancer history with Miltenyi Biotec
On the occasion of World Cancer Day, we talked to Martha Elia Luevano Salinas, an expert for CAR-T cell engineering and application at Miltenyi Biotec, on the latest developments at the frontier of cancer research. Since 1989 our partner Miltenyi Biotec is striving to make a difference for patients who fight cancer every day. Learn more about how Miltenyi Biotec's researchers combine deep biologic knowledge with cutting-edge research technology to identify transformational improvements in the care of cancer patients.
The COVID-19 pandemic has influenced health systems around the world to shift further towards digitalization, but how can that shift be carried out successfully? A “Digitalizing healthcare” paper by Siemens Healthineers provides good examples of how to build a digital enterprise that is successful and sustainable. Read the paper here.
Interest and investment in European healthtech are booming, but what will 2021 bring? Three European investors answer the question and reveal five trends in digital health to look out for. Read the Sifted article here.